Trial Profile
Safety, tolerability and pharmacokinetics (PKs) of multiple oral doses of GR3027 in healthy male volunteers and single and multiple doses in patients with cirrhosis. Preliminary efficacy in cirrhotic patients with evidence of covert hepatic encephalopathy (CHE). A prospective, double-blinded, randomized, placebo-controlled phase I/IIa study
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 20 Jan 2022
Price :
$35
*
At a glance
- Drugs Golexanolone (Primary)
- Indications Hepatic encephalopathy
- Focus Adverse reactions
- Sponsors Umecrine Cognition
- 24 Mar 2021 Results published in the Journal of Hepatology
- 12 Feb 2020 this trial has been completed in Denmark, according to eudra record.
- 06 Feb 2020 This trial has been completed in Hungary (Global End Date: 20 Jan 2020), according to European Clinical Trials Database record.